OPNT004

OPNT004 (drinabant) is a small‑molecule, high‑affinity cannabinoid type 1 (CB1) receptor antagonist being developed as an injectable, parenteral treatment for cannabinoid‑related toxicities, including acute cannabinoid overdose and cannabinoid hyperemesis syndrome. It was originally discovered and developed by Sanofi (as AVE1625) for central nervous system and metabolic indications such as Alzheimer’s disease, schizophrenia, dyslipidemia, type 2 diabetes, and cognitive dysfunction, reaching Phase 2 before those programs were discontinued, and was later in‑licensed by Opiant Pharmaceuticals (now part of Indivior) for repurposing in addiction and overdose settings.[3][4][5][7][11] Opiant, with support from the U.S. National Center for Advancing Translational Sciences, is formulating an injectable version intended for emergency department use to rapidly counteract the effects of excessive tetrahydrocannabinol (THC) and other cannabinoids, for which no approved therapies currently exist.[4][9][10] By blocking CB1 receptors in the central nervous system and periphery, drinabant is expected to reverse cannabinoid‑induced symptoms such as anxiety, paranoia, hallucinations, nausea, vomiting, and related autonomic and gastrointestinal effects.[1][4][9][12]

Other names

drinabant